nbi 27914 has been researched along with 6-hydroxydopa in 1 studies
| Studies (nbi 27914) | Trials (nbi 27914) | Recent Studies (post-2010) (nbi 27914) | Studies (6-hydroxydopa) | Trials (6-hydroxydopa) | Recent Studies (post-2010) (6-hydroxydopa) |
|---|---|---|---|---|---|
| 76 | 0 | 29 | 113 | 0 | 24 |
| Protein | Taxonomy | nbi 27914 (IC50) | 6-hydroxydopa (IC50) |
|---|---|---|---|
| DNA-(apurinic or apyrimidinic site) endonuclease | Homo sapiens (human) | 0.11 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 1.1 | |
| Bile acid receptor | Homo sapiens (human) | 7.92 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T; Forman, BM; Lin, W; Yu, DD | 1 |
1 other study(ies) available for nbi 27914 and 6-hydroxydopa
| Article | Year |
|---|---|
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
Topics: Biological Assay; Drug Discovery; Fluoresceins; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Gene Expression Regulation; Isoxazoles; Molecular Structure; Protein Binding; Receptors, Cytoplasmic and Nuclear | 2013 |